Pear Therapeutics Completes $64M Series C Financing

Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced that it has successfully closed a $64 million Series C financing led by Temasek, and joined by other existing investors including Novartis, 5AM Ventures, Arboretum Ventures, Jazz Venture Partners, The Bridge Builders Collaborative, and Singapore-based EDBI.